Safety and efficacy of switching from dulaglutide to tirzepatide across clinically relevant baseline characteristics in participants with T2D: subgroup analysis of SURPASS-SWITCH - PubMed
6 hours ago
- #Diabetes
- #Incretins
- #Clinical Trial
- Switching from dulaglutide to tirzepatide in patients with type 2 diabetes led to significantly greater reductions in HbA1c and body weight at week 40 compared to continuing dulaglutide across all baseline subgroups analyzed.
- Greater HbA1c reductions were observed in subgroups with higher baseline HbA1c and lower baseline BMI, and greater weight reduction was seen in the non-Hispanic or non-Latino subgroup, while safety profiles remained similar across all subgroups with nausea and diarrhea as common adverse events.
- The analysis concludes that switching to tirzepatide is well-tolerated and provides a clinical alternative for patients not achieving treatment goals with dulaglutide across diverse baseline characteristics.